Atopic Dermatitis

A recent study found no significant correlation between childhood atopic dermatitis and an increase in cardiovascular risk markers.

The INTEGUMENT-OLE study results highlight the long-term efficacy and safety of roflumilast cream for pediatric patients with atopic dermatitis.

A phase 3 trial shows that lebrikizumab improves skin clearance and itch in infants and children with moderate to severe atopic dermatitis.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Phase 2b maintenance data show sustained and new EASI, vIGA-AD, and itch responses with monthly or quarterly rezpegaldesleukin.

In LEVEL UP period 2, most patients who switched from dupilumab to upadacitinib achieved higher skin clearance and itch relief by 16 weeks.

Phase 2 INTEGUMENT-INFANT study results show roflumilast cream 0.05% was well tolerated and improved disease severity in infants with atopic dermatitis.

Findings from phase 3 SHORE and COAST 2 trials showed amlitelimab met key efficacy end points in moderate to severe atopic dermatitis, supporting planned regulatory submissions.

A national survey found most patients with chronic inflammatory skin disease rely on flare-based care and report concerns about long-term topical steroid use.

Vimal H. Prajapati, MD, discusses the latest roflumilast cream data from the INTEGUMENT-PED trial for pediatric atopic dermatitis.

Sub-analysis of ADORING trials shows VTAMA cream improved skin clearance, symptoms, and patient-reported outcomes in children aged 2-17.

Panelists discuss how individualized strategies combining steroids, nonsteroidal agents, and caregiver education promote sustained disease control in children.

Panelists discuss how nonsteroidal PDE-4 and JAK inhibitors offer effective, targeted relief while addressing caregiver concerns about safety and chronic use.

Panelists discuss how calcineurin inhibitors can be safely and effectively used in children with proper education and clinical oversight.

A single injection once per 8 weeks vs once per 4 weeks demonstrated similar levles of skin clearance, for AD patients 12 years and older, according to a Fall Clinical announcement.

New patient- and caregiver-reported outcomes across 3 phase 3 trials demonstrated improved itch and reduced impact of AD on sleep in patients 2 years and older.

Panelists discuss how corticosteroids remain essential for controlling flares but must be used thoughtfully with education and reassurance for families.

Panelists discuss how individualized, consistent topical care helps build trust, promotes adherence, and prevents disease flare-ups in children with AD.

Panelists discuss how treatment goals should center on the child’s comfort, sleep quality, and emotional well-being, not just visible skin improvement.

Panelists discuss how atopic dermatitis affects not only the child’s comfort and confidence but also family well-being and emotional health.

A pair of roflumilast clinical trial investigators react to the FDA approval of the 0.05% formulation to treat atopic dermatitis in children aged 2 to 5 years.

The once-daily, steroid-free cream can be used anywhere on the body for treatment and for any duration, according to Arcutis.

From another potential treatment for pediatric atopic dermatitis, to STI therapy for uncomplicated urogenital gonorrhea, take a look ahead at key PDUFA dates in Q4.

Rezpegaldesleukin improved disease severity and patient-reported outcomes in a phase 2b atopic dermatitis trial with sustained benefit.

The FDA has approved an additional indication for Incyte's ruxolitinib cream to include pediatric patients.